A comparative study of cefozopran for chronic respiratory tract infections

Hiroyuki Kobayashi, Shin Kawai, Sokichi Onodera, Hitoshi Nakano, Tadakatsu Tsuji, Junichi Maruyama, Tetsuo Shimizu, Nobuhiro Sasaki, Shuji Yamaguchi, Yasuo Ohki, Yutaka Nishigaki, Akira Saito, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Tsugio Terai, Takashi Yoshikawa, Yasuto Iida, Kazuyuki Kato, Hidenori YashimaKazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Masakatsu Matsukawa, Ken Osonoi, Masashi Tamura, Kazuki Konishi, Kazuo Obara, Osamu Katagiri, Taiji Yoshida, Masao Sato, Tamotsu Takishima, Yasuo Tanno, Masakichi Motomiya, Akira Watanabe, Yutaka Tokue, Kazuo Sato, Shigeo Takizawa, Mikae Nakamura, Masaaki Arakawa, Kohichi Wada, Fumihide Iwata, Shigeyuki Hoshino, Hiroki Tsukata, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Hazime Takeda, Osamu Sakai, Kohya Shiba, Kazuhisa Okada, Hisao Nakamura, Hiroichi Tanimoto, Kazuo Obara, Katsumi Komatsuzaki, Osamu Tanabe, Kaoru Shimada, Yasuyuki Sano, Yasuo Arai, Takashi Inamatsu, Masaru Koyama, Kohichiro Nakata, Kohji Narui, Izumi Hayashi, Hideo Ikemoto, Harumi Shishido, Hisashi Watanabe, Jingoro Shimada, Seiji Hori, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Takashi Ogura, Midori Sumitomo, Yasuhiro Yoshiike, Yoshihiro Hirai, Eri Hagiwara, Takashi Sakuma, Shoichiro Irimajiri, Seiji Mita, Takao Okubo, Hirotada Ikeda, Yoshiki Murakoshi, Makoto Kudo, Kenji Tani, Tamotsu Kaneko, Toshio Nakamura, Toshiki Iwabuchi, Hideyuki Hasegawa, Masao Nakamura, Akira Shoji, Atsuhiko Sato, Kingo Chida, Shiro Imokawa, Hideki Suganuma, Ryoji Tamura, Takeshi Yagi, Masahiko Okano, Jinichiro Akiyama, Masami Taniguchi, Noriko Kita, Hirokazu Okano, Toshihiko Takeuchi, Yasuo Yamada, Toshinobu Yamamoto, Hidekazu Hanaki, Shinji Takeyama, Yoshimitsu Hayashi, Kazuhide Yamamoto, Hiromi Kato, Tadashi Kobayashi, Tatsuto Uno, Hidehiko Suzuki, Takateru Izumi, Koich Nishimura, Hiroshi Koyama, Naoki Fujimura, Kohei Hamamoto, Hitoshi Asamoto, Yoshihiro Ueda, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Fumio Mikia, Takehiko Kobayashi, Rinzo Soejima, Yoshihito Niki, Masaru Sumi, Osamu Moriya, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michiro Yamakido, Kenji Hasegawa, Takeshi Isobe, Tohru Kurimura, Takahiko Hiramoto, Kohji Takeda, Mamoru Toyofuku, Yoshiro Sawae, Michio Fukuma, Shinji Nakajima, Takashi Ito, Koji Takaki, Kiyoshi Ninomiya, Yukiko Kumagai, Kotaro Ohizumi, Yoichiro Ichikawa, Naoto Tokunaga, Soichirou Ide, Masashi Kawahara, Hironari Shigematsu, Akira Nagata, Yumi Fukuda, Kazuma Fujino, Fumio Tanaka, Hiroaki Furuno, Yoshiyuki Mitsutake, Kozo Ishii, Kohei Hara, Shigeru Kohno, Hironobu Koga, Masato Yatsugi, Kazuo Sasayama, Naomi Ito, Kazuhiro Okuno, Kiyoyasu Fukushima, Akira Ishizaki, Koichi Watanabe, Tohru Ishino, Yuichi Inoue, Sadahiro Asai, Naofumi Suyama, Hideo Mashimoto, Keizo Matsumoto, Takeshi Nagatake, Atsushi Takahashi, Hidehiko Hirose, Yoshihiko Ikeda, Toshihiro Morito, Hiroyuki Yoshimine, Hiroshi Tanaka, Naoto Rikitomi, Tasuku Sakamoto, Masakazu Takasugi, Satoshi Degawa, Mikio Taguchi, Masashi Yamamoto, Kiyoshi Shima, Shinobu Takenaka, Nahomi Hirata, Shigeru Matsukura, Yasumasa Doutsu, Junichi Ashitani, Masaru Nasu, Tohru Yamazaki, Yoichiro Goto, Hiroyuki Nagai, Takayoshi Tashiro, Jun Goto, Kazuo Kitagawa, Saburo Urakami, Hiroshi Nagaoka, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Nobuchika Kusano, Mitsuhiko Futenma, Daishiro Kitagawa, Mamoru Miyagi, Hiroshi Teruya, Nobuya Ogawa, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

The clinical efficacy, safety and utility of cefozopran (CZOP), a new eephem antibiotic, were evaluated in chronic respiratory infections in a comparative study versus ceftazidime (CAZ), Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days, and the forllowing results were obtained: 1. A total of 264 patients were enrolled in this study. Efficacy rates (“good” or better responses) were 91.0% (101/111) in the CZOP group and 88.3% (106/120) in the CAZ group, with no significant difference between the two groups. 2. Bacteriologically, eradication rates were 91.5% (65/71) in the CZOP group and 85.3% (64/ 75) in the CAZ group, with no significant difference between the two groups. 3. Adverse reactions occurred in 8 of the 122 patients in the CZOP group and in 3 of the 126 patients in the CAZ group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 27.7% (33/119) in the CZOP group and 19.8% (25/ 126) in the CAZ group with no significant difference between the two groups. 4. The usefulness rates (“useful” or better evaluations) were 87.6% (99/113) in the CZOP group and 86.0% (104/121) in the CAZ group, with no significant difference between the two groups. No significant differences were observed between the two groups with respect to any of the above parameters. These results indicate that CZOP is useful for the treatment of chronic respiratory tract infections.

Original languageEnglish
Pages (from-to)989-1017
Number of pages29
JournalChemotherapy
Volume41
Issue number9
DOIs
Publication statusPublished - 1993

Keywords

  • cefozopran
  • ceftazidime
  • chronic respiratory tract infection
  • comparative study

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Access to Document

Fingerprint Dive into the research topics of 'A comparative study of cefozopran for chronic respiratory tract infections'. Together they form a unique fingerprint.

Cite this